Multiple complementary assay platforms were used in order to develop consensus regarding the types of techniques/platforms that provide accurate detection and confirmation of these autoantibodies.
Our data demonstrated that the use of a multiple cytokine assay platform was suitable for identifying distinct cytokine profiles associated with the dengue clinical manifestations and severity.
However, more recent data suggest that the use of a multiple cytokine assay platform allows identification of distinct cytokine profiles associated with sepsis severity, evolution of organ failure and death [ 10].
In addition, assay platforms such as ELISPOT, chromium (Cr51) lysis and proliferation (CFSE dilution or H3-thymidine uptake) have a limited capacity to measure multiple immune functions.
Topic modeling was applied to a very large toxicogenomics dataset containing microarray gene expression data from >15,000 samples associated with 131 drugs tested in three different assay platforms (i.e., in vitro assay, in vivo repeated dose study and in vivo single dose experiment) with a design including multiple doses and time points.
There are three assay platforms for SH2 profiling: quantitative far-Western, rosette, and oligonucleotide-tagged multiplex (OTM) assays [ 10].
Interassay reproducibility was assessed when one laboratory tested multiple assays representing the four major cytokine detection platforms, e.g., absorbance ELISA (BioSource), chemiluminescence ELISA (QuantiGlo), fluorimetric immunobead assay (Beadlyte Luminex), and electrochemiluminescence assay (MSD).
The multiplex system we developed in this study is ideally suited to the simultaneous analysis of multiple biomarkers because it uses a standardized assay platform and is highly automated, allowing high-throughput reproducibility across clinical laboratories.
By focusing on such direction of expression change measured by similarly behaving multiple genes, the analysis may become less affected by difference in experimental condition and assay platform.
